Pinnacle Wealth Management Advisory Group LLC Grows Position in iShares Nasdaq Biotechnology ETF (IBB)

Pinnacle Wealth Management Advisory Group LLC boosted its holdings in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 10.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,545 shares of the financial services provider’s stock after purchasing an additional 250 shares during the quarter. Pinnacle Wealth Management Advisory Group LLC’s holdings in iShares Nasdaq Biotechnology ETF were worth $245,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Morgan Stanley raised its position in iShares Nasdaq Biotechnology ETF by 3.7% during the 3rd quarter. Morgan Stanley now owns 4,026,110 shares of the financial services provider’s stock worth $490,944,000 after buying an additional 143,209 shares during the last quarter. Alliancebernstein L.P. raised its position in iShares Nasdaq Biotechnology ETF by 36.2% during the 3rd quarter. Alliancebernstein L.P. now owns 737,179 shares of the financial services provider’s stock worth $89,892,000 after buying an additional 195,746 shares during the last quarter. PNC Financial Services Group Inc. raised its position in iShares Nasdaq Biotechnology ETF by 4.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 670,311 shares of the financial services provider’s stock worth $81,736,000 after buying an additional 31,175 shares during the last quarter. Lockheed Martin Investment Management Co. raised its position in iShares Nasdaq Biotechnology ETF by 173.9% during the 4th quarter. Lockheed Martin Investment Management Co. now owns 417,400 shares of the financial services provider’s stock worth $40,250,000 after buying an additional 265,000 shares during the last quarter. Finally, Bank of Montreal Can raised its position in iShares Nasdaq Biotechnology ETF by 21.2% during the 4th quarter. Bank of Montreal Can now owns 356,482 shares of the financial services provider’s stock worth $34,376,000 after buying an additional 62,272 shares during the last quarter. Hedge funds and other institutional investors own 66.51% of the company’s stock.

Shares of iShares Nasdaq Biotechnology ETF stock opened at $109.42 on Wednesday. iShares Nasdaq Biotechnology ETF has a one year low of $89.01 and a one year high of $122.97.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.com-unik.info/2019/02/13/pinnacle-wealth-management-advisory-group-llc-grows-position-in-ishares-nasdaq-biotechnology-etf-ibb.html.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

See Also: What is a closed-end mutual fund (CEF)?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit